{"acquisitions":[],"changes":[],"country":"US","description":"Sidewinder Therapeutics develops bispecific antibody-drug conjugates that target receptor co-complexes on solid tumors. It serves patients with difficult-to-treat solid cancers who need better therapeutic options. By binding two receptors at once, its conjugates aim to improve tumor cell internalization and widen the therapeutic window.","domain":"sidewinderbio.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":32.71742,"lng":-117.162772,"location":"San Diego","multiples":[],"name":"Sidewinder Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":60000000,"connectionsAmong":[],"currency":"USD","date":"2025-08-10","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"sidewinderbio-com-2025-08-10-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"sidewinderbio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-06-17","status":"attributed","url":null},{"fact":"existence","publisher":"sidewinderbio.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://sidewinderbio.com"},{"fact":"description","publisher":"sidewinderbio.com","retrievedAt":"2026-06-17","status":"self-reported","url":"https://sidewinderbio.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["all in one seo 4.9.5.1","all in one seo pack 4.9.5.1","bugherd","cdnjs","cloudflare","cloudflare bot management","doubleclick floodlight","google analytics","google tag manager","gravity forms 2.9.31","http/3","jquery migrate 3.4.1"],"totalRaisedUsd":90000000,"traction":[],"updatedAt":"2026-06-17","valuations":[]}